All In Biotech

Drug Trial Radar · NCT07899632

A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors

An Open-Label, Single-Arm, Multicenter, Dose-Escalation and Dose-Expansion Phase 1/2I/II Study for the Safety, Tolerability and Preliminary Efficacy of MDSY-1240, a STAT3 Degrader, in Participants With Hematologic Malignancies and Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Aug 2029

Study completion Sep 2029

Sponsor

Lead sponsor
Medsyn Biopharma, LLCIndustry
Sponsor type
Industry
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors. The main goals of this study are to: * Find the recommended dose of MDSY-1240 that can be safely given to participants * Learn more about the side effects and effectiveness of MDSY-1240

Conditions

  • Triple-Negative Breast Cancer (TNBC)
  • Gastric Cancer (GC)
  • Gastric Cancer Adenocarcinoma Metastatic
  • Ovarian Cancer Metastatic
  • Ovarian Cancer Metastatic Recurrent
  • Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
  • Hepatocellular Carcinoma Metastatic
  • Classical Hodgkin Lymphoma Relapsed
  • Cutaneous T-Cell Lymphoma/Mycosis Fungoides
  • Cutaneous T-Cell Lymphoma/Sezary Syndrome
  • Cutaneous T-Cell Lymphomas
  • Peripheral T-cell Lymphoma (PTCL)
  • Large Granular Lymphocytic Leukemia (LGL-L)
  • T-Cell Large Granular Lymphocytic Leukemia

Interventions

  • MDSY-1240Drug

    Participants will receive MDSY-1240 Intravenously (IV) on days 1, 8, 15, and 22 in a 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (Dose Escalation): Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days.
  2. Part 1 (Dose Escalation): Number of Participants With Serious Adverse Events (SAEs)Time frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
  3. Part 1 (Dose Escalation): Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
  4. Part 1 (Dose Escalation): Number of Participants With Treatment-Related Adverse Events (TRAEs)Time frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
  5. Part 1 (Dose Escalation): Number of Participants With Dose Interruptions Due to Adverse EventsTime frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
  6. Part 1 (Dose Escalation): Number of Participants With Treatment Discontinuations Due to Adverse EventsTime frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
  7. Part 1 (Dose Escalation): Number of Participants With Infusion-Related Reactions (IRRs)Time frame: From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days
  8. Part 1 (Dose Escalation): Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: During the Dose-Limiting Toxicity (DLT) evaluation period from Cycle 1 Day 1 through Day 22 of Cycle 1.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.